Osmetech acquired the Opti product line from Roche Diagnostics. Opti is the portable analysis technology for bloodgas and electrolytes measurement. This highly successful analyser has also taken the veterinary world by storm. IDEXX Laboratories Inc (IDXX) have entered into a ten year OEM agreement to provide the customised OPTI analysers to the veterinary field under the brand VetStat.

In September 2004 the company acquired the "OPTIgene" (Genedrive) product from MS this technology will enable OMH a strong entry point into the fastest growing market segment of DNA based diagnostics. A market that is growing at an annual rate of 20% and is currently worth $ 22 bln !

In the latest acquisition 1/7/05 Osmetech acquired Clinical Micro Sensors from Motorola PLC, OMH plans to utilise the eSensor technology coupled with OPTIgene to address the majority of existing and new tests in the genetic diagnostics market. 'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and OMH believes that these products have significant market potential.

Scroll & Click for Websites & Other LinksRT Mag Wall Street Reporter Interviews JW

Up Coming Events in 2006

CMS CYP450 product Launch!!!!!............................................. 2006

IDEXX critical care platform Launch!!!!!....................................2006/7....much more to follow

Click Here to Track Osmetech's Progress in the "Stocks That Could Double in 2006" Competition

when the price has crept back to recent highs further good news from the company should propel it back to the 30-40p level. Given that we are expecting a strong results update In Januray the start of 2007 could be very interesting!

hobbst your totally correct in your observations.

Motoring today. Up 8% plenty more to come.
Lookng good

Incidentally the price hasn't stop motoring since the thread 'zits' popped up.

60% in 6 weeks will do for starters, with no fund raising needs (like last year) the resistance at mid 30p's should be a piece of cake.

RNS Number:0992M
Osmetech PLC
15 November 2006



Osmetech increases patent holdings November 15, 2006


Pasadena, California, USA - Osmetech Molecular Diagnostics (Osmetech), a fast
developing, international diagnostics business serving the high growth, near
patient molecular testing market, today announced that it has been granted a UK
patent covering its OPTI TUBETM plastic capillary product. The grant of the UK
patent follows the recent registration of a German Utility Model which also
covers Osmetech's innovative plastic vessel. The tube is made from cyclic olefin
and has excellent rigidity, optical and thermal properties making it the product
of choice for PCR thermal cycling and other applications that traditionally
employ breakable glass. Adding to this versatility and novelty, Osmetech also
sells a carousel housing for the OPTI TUBEs that fits the Roche Lightcycler(R).

The new patent, GB 2409659, is just one of a number of patents issued to
Osmetech in the last six months, according to Edward Kreusser, Osmetech's VP of
Intellectual Property and Legal Affairs. Osmetech now owns or holds exclusive
rights to some 130 patents worldwide (70 US) mostly in the field of
electrochemical detection for biological entities such as nucleic acids and
proteins which offers significant advantages over other methods.

Osmetech's growing patent estate boasts tens of millions in investment over the
last decade from Motorola, Caltech, Harvard University and the University of
North Carolina who continue to have a vested interest in the technology and are
pleased to see the great commercial potential of the portfolio become a reality.

This latest development builds on momentum achieved earlier this year when
Osmetech received FDA approval to launch its eSensor(R) electrochemistry-based
array system for cystic fibrosis carrier detection. In addition to other
projects, Osmetech plans to follow with a battery of related pharmacogenomic
CYP450 assays emploing the same electrochemical detection platform.

Contact Osmetech:

Edward Kreusser, Esq.

Reckon we could see a chart breakout today.

MajorShareHolders No. Shares(%) Gartmore 31,279,344(15.42) Schroder 27,966,506(13.79) UBS AG 23,797,239(11.73) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 118,258,550(58.31)

Nice chart breakout under way.

Looks like it is going to pop. I wonder if some deal was hacked at Medica or AMP last week?

New trade marks for Molecular Products have been registered recently.

Say hello to TRITON and IMPLUSE. Interestingly they are registered under the Molecular Diagnostics brand rather than just Osmetech.

Word Mark TRITON
Goods and Services IC 009. US 021 023 026 036 038. G & S: Medical invitro diagnostic devices and modules that employ electrochemical detection of target analytes
Standard Characters Claimed
Mark Drawing Code (4) STANDARD CHARACTER MARK
Design Search Code
Serial Number 77038992
Filing Date November 7, 2006
Current Filing Basis 1B
Original Filing Basis 1B
Owner (APPLICANT) Osmetech Molecular Diagnostics CORPORATION DELAWARE 757 S. Raymond Ave. Pasadena CALIFORNIA 91105
Type of Mark TRADEMARK
Register PRINCIPAL
Live/Dead Indicator LIVE




Word Mark IMPULSE
Goods and Services IC 009. US 021 023 026 036 038. G & S: Medical invitro diagnostic devices and modules that employ electrochemical detection of target analytes
Standard Characters Claimed
Mark Drawing Code (4) STANDARD CHARACTER MARK
Design Search Code
Serial Number 77038972
Filing Date November 7, 2006
Current Filing Basis 1B
Original Filing Basis 1B
Owner (APPLICANT) Osmetech Molecular Diagnostics CORPORATION DELAWARE 757 S. Raymond Ave. Pasadena CALIFORNIA 91105
Type of Mark TRADEMARK
Register PRINCIPAL
Live/Dead Indicator LIVE

Major holders table updated. UBS being the latest buyers

MajorShareHolders No. Shares(%) Gartmore 31,279,344(15.42) Schroder 27,966,506(13.79) UBS AG 25,346,239 (12.5) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 119,807,550 (59.08)

Todays Breakout of the inverse head and shouldes give a short term price target of c 32p

Nice continuation of the breakout today.

looking good

Moving up again.

OMH - now Gartmore's second largest holding!

http://www.advfn.com/p.php?pid=nmona&cb=1165236703&symbol=gsm&article=0018245385

Nicely on track for the c32p price projection based on the highly accurate inverse head and shoulders formation.

Trading Statement due early 2007

Some big BUY's put through after hours.

Time Price Quantity Type Bid Offer Buy/Sell Total Buy Total Sell Total Unknown
07/12/06 17:06 27.027 500,000 B 25.0 28.0 Buy 856,911 748,631 380,000
07/12/06 16:34 27.0 500,000 O 25.0 28.0 Buy 1,431,911 748,631 380,000
07/12/06 16:34 27.0 500,000 O 25.0 28.0 Buy 1,931,911 748,631 380,000
07/12/06 17:11 26.92 425,000 O 25.0 28.0 Buy 2,356,911 748,631 380,000

<>

Are we expecting the results at the end of january bangers?

I should think around that time but there's the Trading Statement to look forward to first! And perhaps more BIG news in the mean time!?

Considering in July OMH were forecasting 'record sales performance
during the next six month period' i would expect this TS to be more than upbeat.

Would you expect the price to rise prior to the TS & results then?